Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 922.5 GBX 0.87%
Market Cap: 1.2B GBX
Have any thoughts about
Indivior PLC?
Write Note

Gross Margin
Indivior PLC

83%
Current
83%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83%
=
Gross Profit
952m
/
Revenue
1.1B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
UK
Indivior PLC
LSE:INDV
1.2B GBP
83%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
69%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
77%
CH
Roche Holding AG
SIX:ROG
197.2B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
159B GBP
82%
CH
Novartis AG
SIX:NOVN
169.7B CHF
75%
US
Pfizer Inc
NYSE:PFE
149.4B USD
71%
Country UK
Market Cap 1.2B GBP
Gross Margin
83%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 729.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.6T DKK
Gross Margin
85%
Country US
Market Cap 347.8B USD
Gross Margin
69%
Country US
Market Cap 248.3B USD
Gross Margin
77%
Country CH
Market Cap 197.2B CHF
Gross Margin
73%
Country UK
Market Cap 159B GBP
Gross Margin
82%
Country CH
Market Cap 169.7B CHF
Gross Margin
75%
Country US
Market Cap 149.4B USD
Gross Margin
71%
No Stocks Found

Indivior PLC
Glance View

Market Cap
1.2B GBX
Industry
Pharmaceuticals

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
2 223 GBX
Undervaluation 59%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83%
=
Gross Profit
952m
/
Revenue
1.1B
What is the Gross Margin of Indivior PLC?

Based on Indivior PLC's most recent financial statements, the company has Gross Margin of 83%.